CRISPR Therapeutics AG (CRSP) Common Equity (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Common Equity data on file, last reported at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 0.8% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (down 0.8% YoY), and the FY2025 full-year result was $1.9 billion, down 0.53% from the prior year.
• Common Equity retreated to $1.8 billion in Q1 2026, from $1.9 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.2 billion in Q1 2022 to a low of $1.7 billion in Q2 2025.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2025 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 24.34% in 2022, while the deepest fall reached 22.24% in 2022.
• Tracing CRSP's Common Equity over 5 years: stood at $1.9 billion in 2022, then gained by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then decreased by 0.53% to $1.9 billion in 2025, then declined by 5.58% to $1.8 billion in 2026.
• Business Quant data shows CRSP's Common Equity at $1.8 billion in Q1 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q3 2025.